Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Porcine Vaccines Market

ID: MRFR/Pharma/48725-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

China Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Porcine Vaccines Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  49.     4.1.1 Inactivated vaccines
  50.     4.1.2 Live attenuated vaccines
  51.     4.1.3 Toxoid vaccines
  52.     4.1.4 Recombinant vaccines
  53.     4.1.5 Conjugate vaccines
  54.     4.1.6 DNA vaccines
  55.   4.2 Food, Beverages & Nutrition, BY Disease Indication (USD Million)
  56.     4.2.1 PED (Porcine Epidemic Diarrhea)
  57.     4.2.2 PRRS (Porcine Reproductive & Respiratory Syndrome)
  58.     4.2.3 Swine influenza
  59.     4.2.4 Aujeszky's disease (AD)
  60.     4.2.5 Porcine Circovirus Associated Disease (PCVAD)
  61.     4.2.6 Others
  62.   4.3 Food, Beverages & Nutrition, BY End-user (USD Million)
  63.     4.3.1 Veterinary Hospitals
  64.     4.3.2 Hog Production Farm
  65. 5 SECTION V: COMPETITIVE ANALYSIS
  66.   5.1 Competitive Landscape
  67.     5.1.1 Overview
  68.     5.1.2 Competitive Analysis
  69.     5.1.3 Market share Analysis
  70.     5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  71.     5.1.5 Competitive Benchmarking
  72.     5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  73.     5.1.7 Key developments and growth strategies
  74.       5.1.7.1 New Product Launch/Service Deployment
  75.       5.1.7.2 Merger & Acquisitions
  76.       5.1.7.3 Joint Ventures
  77.     5.1.8 Major Players Financial Matrix
  78.       5.1.8.1 Sales and Operating Income
  79.       5.1.8.2 Major Players R&D Expenditure. 2023
  80.   5.2 Company Profiles
  81.     5.2.1 Zoetis (US)
  82.       5.2.1.1 Financial Overview
  83.       5.2.1.2 Products Offered
  84.       5.2.1.3 Key Developments
  85.       5.2.1.4 SWOT Analysis
  86.       5.2.1.5 Key Strategies
  87.     5.2.2 Merck Animal Health (US)
  88.       5.2.2.1 Financial Overview
  89.       5.2.2.2 Products Offered
  90.       5.2.2.3 Key Developments
  91.       5.2.2.4 SWOT Analysis
  92.       5.2.2.5 Key Strategies
  93.     5.2.3 Boehringer Ingelheim (DE)
  94.       5.2.3.1 Financial Overview
  95.       5.2.3.2 Products Offered
  96.       5.2.3.3 Key Developments
  97.       5.2.3.4 SWOT Analysis
  98.       5.2.3.5 Key Strategies
  99.     5.2.4 Elanco Animal Health (US)
  100.       5.2.4.1 Financial Overview
  101.       5.2.4.2 Products Offered
  102.       5.2.4.3 Key Developments
  103.       5.2.4.4 SWOT Analysis
  104.       5.2.4.5 Key Strategies
  105.     5.2.5 Ceva Santé Animale (FR)
  106.       5.2.5.1 Financial Overview
  107.       5.2.5.2 Products Offered
  108.       5.2.5.3 Key Developments
  109.       5.2.5.4 SWOT Analysis
  110.       5.2.5.5 Key Strategies
  111.     5.2.6 Virbac (FR)
  112.       5.2.6.1 Financial Overview
  113.       5.2.6.2 Products Offered
  114.       5.2.6.3 Key Developments
  115.       5.2.6.4 SWOT Analysis
  116.       5.2.6.5 Key Strategies
  117.     5.2.7 Heska Corporation (US)
  118.       5.2.7.1 Financial Overview
  119.       5.2.7.2 Products Offered
  120.       5.2.7.3 Key Developments
  121.       5.2.7.4 SWOT Analysis
  122.       5.2.7.5 Key Strategies
  123.     5.2.8 Vetoquinol (FR)
  124.       5.2.8.1 Financial Overview
  125.       5.2.8.2 Products Offered
  126.       5.2.8.3 Key Developments
  127.       5.2.8.4 SWOT Analysis
  128.       5.2.8.5 Key Strategies
  129.   5.3 Appendix
  130.     5.3.1 References
  131.     5.3.2 Related Reports
  132. 6 LIST OF FIGURES
  133.   6.1 MARKET SYNOPSIS
  134.   6.2 CHINA MARKET ANALYSIS BY TYPE
  135.   6.3 CHINA MARKET ANALYSIS BY DISEASE INDICATION
  136.   6.4 CHINA MARKET ANALYSIS BY END-USER
  137.   6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
  138.   6.6 RESEARCH PROCESS OF MRFR
  139.   6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
  140.   6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  141.   6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  142.   6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
  143.   6.11 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
  144.   6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
  145.   6.13 FOOD, BEVERAGES & NUTRITION, BY DISEASE INDICATION, 2024 (% SHARE)
  146.   6.14 FOOD, BEVERAGES & NUTRITION, BY DISEASE INDICATION, 2024 TO 2035 (USD Million)
  147.   6.15 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 (% SHARE)
  148.   6.16 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 TO 2035 (USD Million)
  149.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  150. 7 LIST OF TABLES
  151.   7.1 LIST OF ASSUMPTIONS
  152.     7.1.1
  153.   7.2 China MARKET SIZE ESTIMATES; FORECAST
  154.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  155.     7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Million)
  156.     7.2.3 BY END-USER, 2025-2035 (USD Million)
  157.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  158.     7.3.1
  159.   7.4 ACQUISITION/PARTNERSHIP
  160.     7.4.1

China Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

  • Inactivated vaccines
  • Live attenuated vaccines
  • Toxoid vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • DNA vaccines

Food, Beverages & Nutrition By Disease Indication (USD Million, 2025-2035)

  • PED (Porcine Epidemic Diarrhea)
  • PRRS (Porcine Reproductive & Respiratory Syndrome)
  • Swine influenza
  • Aujeszky's disease (AD)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

Food, Beverages & Nutrition By End-user (USD Million, 2025-2035)

  • Veterinary Hospitals
  • Hog Production Farm

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓